Trials to overcome drug resistance to EGFR and ALK targeted therapies - past, present and future
Molecularly targeted agents (MTAs) are changing the therapeutic landscape in advanced non-small cell lung cancer (NSCLC). Since the discovery of sensitizing mutations in the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) domain, clinical investigations have focused on...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00233/full |